ECE2021 Audio Eposter Presentations Reproductive and Developmental Endocrinology (55 abstracts)
Decline in AMH concentrations following radioactive iodine treatment in women with differentiated thyroid cancer: A systematic review and meta-analysis
Panagiotis Anagnostis 1 , Panagiotia Florou 2 , Julia Bosdou 1 , Grigorios Grimbizis 3 , Ioannis Iakovou 4 , Efstratios Kolibianakis 2 & Dimitrios Goulis 1
1Aristotle University of Thessaloniki, Unit of Reproductive Endocrinology, 1st Department of Obstetrics and Gynecology, Medical School, Thessaloniki, Greece; 2Aristotle University of Thessaloniki, Unit of Human Reproduction 1st Department of Obstetrics and Gynecology, Medical School, Thessaloniki, Greece; 31st Department of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece; 4Academic Department of Nuclear Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
Purpose
Radioactive iodine (RAI) is frequently used as adjuvant therapy in patients with differentiated thyroid cancer (DTC). However, its effect on ovarian reserve has not been fully elucidated, with studies yielding inconsistent results. The aim of this study was to systematically review and meta-analyze the best available evidence regarding the effect of RAI on ovarian reserve in premenopausal women with DTC.
Methods
A comprehensive literature search was conducted in PubMed, Cochrane and Scopus, until December 6th, 2020. Data were expressed as weighted mean difference (WMD) with a 95% confidence interval (CI). The I2 index was used to assess heterogeneity.
Results
Four prospective studies were included in the qualitative and quantitative analysis. Anti-Müllerian hormone (AMH) concentrations decreased at three (WMD –1.66 ng/ml, 95% CI –2.42 to –0.91, P < 0.0001; I2 0%), six (WMD –1.58, 95% CI –2.63 to –0.52, P = 0.003; I2 54.7%) and 12 months (WMD –1.62 ng/ml, 95% CI –2.02 to –1.22, P < 0.0001; I2 15.5%) following a single RAI dose compared with baseline (three studies; n = 104). With respect to follicle-stimulating hormone (FSH) concentrations, no difference was observed at six (WMD +3.29 IU/l, 95% CI –1.12 to 7.70, P = 0.14; I2 96.8%) and 12 months (WMD +0.13 IU/l, 95% CI –1.06 to 1.32, P = 0.83; I2 55.2%) post-RAI compared with baseline (two studies; n = 83). No data were available for antral follicle count.
Conclusions
AMH concentrations decrease at three months and remain low at six and 12 months following RAI treatment in women with DTC. No difference in FSH concentrations post-RAI was observed.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more